

Legend		
Plenary	Workshop	Social Event
Industry Session	Poster Session	Debate

Thursday, June 15, 2017

	K2 - 620	K1 - 290	K3 - 290	G1 - 175	J1 - 144
14:00-14:45	Keynote lecture: J. Edmond Charlton Lecture Chair: TBA Individualized pain therapy based on phenotyping: are we there yet? Ralf Baron, Germany				
14:45-15:00	Coffee Break in Exhibition Area				
15:00-16:30	Workshop 1: Chair: Andrew Rice, UK Preparing for the advent of precision medicine for neuropathic pain: profiling and stratification methods in pre-clinical and clinical research <i>Aligning preclinical research methods with the precision medicine agenda</i> Andrew Rice, UK <i>Patient stratification by symptom and sensory profiling in clinical trials</i> Nanna Finnerup, Denmark <i>Patient stratification by endogenous pain modulation measures in clinical trials</i> David Yarnitsky, Israel	Workshop 2: Chair: Theodore Price, USA The pain biography: what early life injury and hyperalgesic priming teaches us about how pain becomes chronic <i>Descending dopaminergic circuits and D5 dopamine receptors in the transition to chronic pain</i> Theodore Price, USA <i>Dorsal horn circuits mediating mechanical allodynia and the transition to a chronic pain state</i> Rebecca Seal, USA <i>Priming of spinal nociceptive processing/circuitry by neonatal injury</i> Simon Beggs, UK	Workshop 3: Chair: Lene Vase Toft, Denmark The contribution of the placebo response in pharmacological, physical- and surgical interventions: state of art, prediction and ethical considerations <i>Discussion of how the placebo response may influence the outcome of clinical trials</i> Lene Vase Toft, Denmark <i>Recent advances in psychological and genetic prediction of the placebo response in clinical trials</i> Andrew Rice, UK <i>Ethical and practical considerations for and against placebo control in the assessment of the effectiveness of physical and surgical analgesic interventions</i> TBA	Workshop 4: Testing sodium channel function in neuropathic pain Chair: Troels Jensen Staehelin, Denmark <i>Can peripheral and central effects of sodium channels be tested in neuropathic pain?</i> Troels Jensen Staehelin, Denmark <i>Heat- and cold-resistant action potentials in nociceptors</i> Katharina Zimmerman, Germany <i>Pharmacological evidence of sodium channel targeted interventions</i> Simon Haroutounian, USA	Workshop 5: Micro-rnas as biomarkers and regulators of neuropathic pain disorders Chair: Nurcan Üçeyler, Germany <i>miRNAs involved in the pathogenesis of neuronal malfunction following nerve injury</i> Nurcan Üçeyler, Germany <i>miRNA containing exosomes for neuroimmune communication in the nervous system</i> Marzia Malcangio, UK <i>miRNAs associated with human CRPS and mouse models of neuropathic pain</i> Alexander Huettenhofer, Austria
16:45-17:30	Opening Ceremony				
17:30 - 19:30	Networking Reception				

Legend

Plenary	Workshop	Social Event
Industry Session	Poster Session	Debate

Friday, June 16, 2017

	K2 - 620	K1 - 290	K3 - 290	G1 - 175	J1 - 144	
07:30-09:00						
09:00-10:00	Plenary Session II Chair: TBA <i>Global Burden of Disease - The impact of neuropathic pain</i> Fiona Blyth, Australia <i>Clinical assessment of neuropathic pain</i> Roy Freeman, USA					
10:00-10:30	Coffee Break, Poster Viewing, Visit Exhibition					
10:30-12:00	Workshop 6: Conditioned pain modulation: lessons learned, unanswered questions, future directions Chair: Serge Marchand, Canada <i>CPM; clinical relevance and unanswered questions</i> Serge Marchand, Canada <i>Exploring individual variability in the experience of pain; what we've learned from fMRI studies</i> Katja Wiech, UK <i>Technical parameters of CPM methodology; important considerations for improving reliability and reporting</i> Donna Kennedy, UK		Workshop 7: How to assess patients with neuropathic pain. facts and fallacies of quantitative sensory testing, neurophysiological techniques and skin biopsy Chair: Andrea Truini, Italy <i>Neurophysiological techniques for dissecting neuropathic pain</i> Andrea Truini, Italy <i>Neuropathic pain: is quantitative sensory testing helpful?</i> Elena Enax-Krumova, Germany <i>Skin biopsy features in chronic pain conditions</i> Nurcan Üçeyler, Germany	Workshop 8: Pre-clinical models of neuropathic pain: what can and can't they tell us, and what should we do about it? Chair: Andrew Rice, UK <i>General overview; basing clinical practice and research on findings derived from pre-clinical models</i> Blair Smith, UK <i>Clinical relevance of existing animal models for neuropathic pain, their strengths and weaknesses and topics for improvement</i> Andrew Rice, UK <i>Existing neuro-imaging models for neuropathic pain, their clinical relevance, strengths and weaknesses and how we might improve them</i> Karen Davis, Canada	Workshop 9: Chronic neuropathic pain in immune-mediated neurological diseases Chair: Aki Hietaharju, Finland <i>Chronic neuropathic pain in immune-mediated peripheral neuropathies</i> Aki Hietaharju, Finland <i>Chronic neuropathic pain in multiple sclerosis</i> Flemming Bach, Denmark <i>Generation of neuropathic pain in neuroimmunological diseases</i> Jacqueline Palace, UK	
12:00-12:30	Break and Visit Exhibition					
12:30-14:00	Poster Discussion Session 1					
14:00-15:00	Plenary Session III Chair: TBA <i>New Treatments for Neuropathic Pain</i> Didier Bouhassira, France <i>Neuromodulation - Spinal Cord Stimulation</i> TBA					
15:30-17:00	Workshop 10: Advances in Spinal Cord Stimulation: Insights on Potential Mechanisms Chair: TBA <i>Status of Clinic and SCS</i> Stephen McMahon, UK <i>Spinal modulatory mechanisms of SCS in experimental models of neuropathic pain</i> Srinivasa Raja, USA <i>fMRI and Experimental SCS</i> Bert Joosten, The Netherlands	Workshop 11: Emerging cell-based therapy for neuropathic pain Chair: Jianguo Cheng, USA <i>Mesenchymal stem cells prevent and reverse opioid tolerance and opioid-induced hyperalgesia</i> Jianguo Cheng, USA <i>Transplantation of cortical GABAergic precursor neurons to treat neuropathic pain and itch</i> Allan Basbaum, USA <i>Bone marrow stromal cells inhibit neuropathic pain via TGF-beta secretion</i> Ru-Rong Ji, USA	Workshop 12: Molecule to man approaches to investigate pathophysiological mechanisms and treatment of neuropathic pain Chair: Sulayman Dib-Hajj, USA <i>Painful and painless sodium channelopathies and strategies for personalized treatment</i> Sulayman Dib-Hajj, USA <i>Developing cellular models of human pain channelopathies</i> David Bennett, UK <i>Genetic approach to painful peripheral neuropathies</i> Catharina Faber, The Netherlands	Workshop 13: Back pain revisited: new insights for research, diagnosis and therapy Chair: Didier Bouhassira, France <i>Subgrouping of back pain patients: where do we stand where do we go?</i> Didier Bouhassira, France <i>New diagnostic tools on the rise – what are they good for?</i> Philipp Hüllemann, Germany <i>Classical and emerging pharmacological treatments for low back pain: where do we stand?</i> John Markman, USA	Workshop 14: How can we accelerate clinical advances from neuropathic pain research? Ideas from The Lancet's "Research: Increasing Value, Reducing Waste" Initiative Chair: Gerd Antes, Germany <i>An overview of the Lancet "Research: Increasing Value, Reducing Waste" initiative</i> Gerd Antes, Germany <i>Waste in pre-clinical neuroscience research with a focus on neuropathic pain</i> Malcolm Macleod, UK <i>Waste in neuropathic pain clinical trials: threats and opportunities</i> Ian Gilron, Canada	
17:00-17:30	Coffee Break, Poster Viewing, Visit Exhibition					
17:30-19:00	Industry Supported Symposia					

Legend

Plenary	Workshop	Social Event
Industry Session	Poster Session	Debate

Saturday, June 17, 2017

	K2 - 620	K1 - 290	K3 - 290	G1 - 175	J1 - 144
07:30-09:00					
09:00-10:00	<p style="text-align: center;">Plenary Session IV Chair: TBA <i>Neuropathic Itch</i> Sarah Ross, USA <i>Is Burning Mouth Syndrome a Neuropathic Pain Condition?</i> Satu Jääskeläinen, Finland</p>				
10:00-10:30	Coffee Break, Poster Viewing, Visit Exhibition				
10:30-12:00	<p style="text-align: center;">Workshop 15: Recent advances in diagnosis and management of painful post-traumatic trigeminal neuropathy Chair: Barry Sessle, Canada <i>The role of non-neural as well as neural elements, chemical mediators and genetic factors in trigeminal neuropathic pain</i> Barry Sessle, Canada <i>New insights into tests of orofacial somatosensory function in the diagnosis of trigeminal neuropathic pain</i> Lene Baad-Hansen, Denmark <i>Management of painful post-traumatic trigeminal neuropathy</i> Peter Svensson, Denmark</p>	<p style="text-align: center;">Workshop 16: Entrapment neuropathies: challenging common beliefs with novel evidence Chair: Annina Schmid, UK <i>The pathophysiology of entrapment neuropathies: from bench to bedside</i> Annina Schmid, UK <i>Does somatosensory phenotype predict the outcome of carpal tunnel surgery?</i> Donna Kennedy, UK <i>I can't have carpal tunnel syndrome, it doesn't hurt!</i> Jeremy Bland, UK</p>	<p style="text-align: center;">Workshop 17: Neuropathic pain regulation by astrocytes, microglia, and macrophages: pre-clinical and clinical evidence Chair: Ru-Rong Ji, USA <i>Distinct roles of microglia and astrocytes in neuropathic pain</i> Ru-Rong Ji, USA <i>Distinct roles of microglia and macrophages in neuropathic pain</i> Marzia Malcangio, UK <i>Imaging glial activation in patients with chronic pain</i> Marco Loggia, USA</p>	<p style="text-align: center;">Workshop 18: Recent advances in the pharmacotherapy of neuropathic pain: focus on botulinum toxin Chair: Nadine Attal, France <i>Botulinum toxin A type A: new data in peripheral neuropathic pain</i> Nadine Attal, France <i>Mechanisms of action of botulinum toxin in peripheral neuropathic pain</i> Bazbek Davletov, UK <i>Perineural injections of botulinum toxin in neuropathic pain</i> Christoph Maier, Germany</p>	<p style="text-align: center;">Workshop 19: Kv1 channels as modulators of hyperexcitability in neuropathic pain Chair: David Bennett, UK <i>Patient autoantibodies against CASPR2 cause pain hypersensitivity in mice via the regulation of VGKC function in sensory neurons</i> John Dawes, UK <i>Altered potassium channel distribution and composition in myelinated axons suppresses hyperexcitability following injury</i> Margarita Calvo, Chile <i>Role of slow inactivating potassium current (IKD) in cold transduction and cold allodynia</i> Rodolfo Madrid, Chile</p>
12:00-12:30	Break and Visit Exhibition				
12:30-14:00	Poster Discussion Session 2				
14:00-15:00	<p style="text-align: center;">Plenary Session V Chair: TBA <i>Application of Optigenetics and Neuropathic Pain</i> Robert Gereau, USA <i>How can genetic studies help our understanding on neuropathic pain?</i> Luda Diatchenko, Canada</p>				
15:30-17:00	<p style="text-align: center;">Debate: Determining small fibre rarefication - is skin punch biopsy (in)dispensable? Chair: TBA <i>CCM to identify nerve fibre and Langerhans cell pathology</i> Rayaz Malik, Qatar <i>Skin biopsy as a gold-standard for assessing the IENFD</i> Giuseppe Lauria, Italy</p>	<p style="text-align: center;">Workshop 20: Genetic and epigenetic regulation of neuropathic pain Chair: Greg Neely, Australia <i>New high throughput models of neuropathic pain</i> Greg Neely, Australia <i>Genomic and transcriptomic profiling of neuropathic pain</i> Michael Costigan, USA <i>Epigenetics and pain - what do we actually know</i> Franziska Denk, UK</p>	<p style="text-align: center;">British Journal of Anaesthesia Sponsored Workshop 21: Cancer chemotherapy induced peripheral neuropathy: new findings from the lab and clinic Chair: Patrick Dougherty, USA <i>Mechanisms of spontaneous activity induced by chemotherapeutic drugs in dorsal root ganglion neurons</i> Patrick Dougherty, USA <i>Clinical aspects of CIPN: trials, treatment, and translation</i> Paul Farquhar-Smith, UK <i>Clinical aspects of CIPN: trials, treatment, and translation</i> Lesley Colvin, UK <i>Oxidative stress and cellular bioenergetics in chemotherapy-induced neuropathies</i> Sarah Flatters, UK</p>	<p style="text-align: center;">Workshop 22: C-tactile afferents in neuropathic pain: from molecular to clinical insights Chair: Hakan Olausson, Sweden <i>The human C-tactile afferent system: observations in healthy subjects and denervated patients</i> Hakan Olausson, Sweden <i>Functional Specialization and circuitry of C-LTMRs</i> Aziz Moqrich, France <i>C-tactile afferent inputs: dynamic conversion between pleasure and pain</i> David Mahns, Australia</p>	<p style="text-align: center;">Workshop 23: A multidisciplinary approach for stratifying patients with peripheral neuropathic pain Chair: Andreas Themistocleous, UK <i>The Pain in Neuropathy Study – deep phenotyping to explore differences between painful and painless diabetic neuropathy</i> Andreas Themistocleous, UK <i>Painful small fibre neuropathy as the result of a skin disorder- the case of Epidermolysis Bullosa</i> Margarita Calvo, Chile <i>Microneurography in acquired and inherited painful neuropathy</i> Jordi Serra, Spain</p>
17:00-17:30	Coffee Break and Visit Exhibition				
17:30-19:00	Industry Supported Symposia				

Legend

Plenary	Workshop	Social Event
Industry Session	Poster Session	Debate

Sunday, June 18, 2017

	K2 - 620	K1 - 290	K3 - 290	G1 - 175	J1 - 144
08:00-09:30	<p>Workshop 24: Immunological mechanisms supporting CRPS: basic, translational and clinical evidence Chair: David Clark, USA <i>IgM pronociceptive effects in CRPS</i> David Clark, USA <i>Immunoglobulin G mediated non-inflammatory autoimmunity in longstanding CRPS</i> Andreas Goebel, UK <i>Immunoglobulin G mediated non-inflammatory autoimmunity in longstanding CRPS: Translational evidence</i> David Andersson, UK <i>Basic, translational and clinical evidence for innate immune mediators in CRPS</i> Tanja Schlereth, Germany</p>	<p>Workshop 25: Sensory, psychological and cognitive factors that shape the trajectory of persistent post-surgical pain (PPSP) Chair: Simon Haroutounian, USA <i>Sensory and cognitive processing and the risk of PPSP: implications for clinical research</i> Simon Haroutounian, USA <i>Persistent post-surgical pain (PPSP): Epidemiology, characteristics and current challenges</i> Patricia Lavand'homme, Belgium <i>Predictive biopsychosocial phenotypes associated with PPSP, and development of a risk algorithm for clinical decision-making</i> Robert Edwards, USA</p>	<p>Workshop 26: Evoked potentials for diagnosing small fiber disease: cool or outdated? Chair: Philipp Hüllemann, Germany <i>Cold evoked potentials- ready for clinical use?</i> Philipp Hüllemann, Germany <i>Why should we combine contact heat (CHEPS) and pinprick evoked potentials (PEPs)?</i> Ulf Baumgärtner, Germany <i>Laser evoked potentials (LEPs) – the “gold standard”</i> Andrea Truini, Italy</p>	<p>Workshop 27: Optogenetic and chemogenetic dissection of central noradrenergic control : relevance to neuropathic pain and its comorbidities Chair: Anthony Pickering, UK <i>Evidence for dichotomous central noradrenergic organisation and its relevance for pain control</i> Anthony Pickering, UK <i>How the Locus Coeruleus influences the affective consequences of chronic pain</i> Esther Berrococo, Spain <i>Dissecting locus coeruleus and amygdala circuit interactions in negative affect and pain</i> Michael Bruchas, USA</p>	<p>Workshop 28: Improving the quality of pain trials Chair: Janne Gierthmühlen, Germany <i>Who is healthy? Aspects to consider when including healthy volunteers</i> Janne Gierthmühlen, Germany <i>Research design considerations for chronic pain clinical trials</i> Jennifer Gewandter, USA <i>Considerations for outcome parameters in clinical pain trials: Is pain assessment a sufficient outcome parameter</i> Peter Tugwell, Canada</p>
09.30-10.00	Coffee Break				
10.00-11.00	Best Poster Session				
11:00-12:00	<p>Plenary Session VI Chair:TBA <i>Inflammation in the pathophysiology of neuropathic pain</i> Claudia Sommer, Germany Debate: Adequacy of diagnostic tools for complex regional pain syndrome Christoph Maier, Germany Stephen Bruehl, USA</p>				
12:00-13:00	Closing Ceremony and Prize Presentations				